Oncology Supercharging clinical trials with data and AI: Realyze’s Aa... At ASCO 2025, Realyze CEO Aaron Brauser talks transforming clinical trial screening with AI, NLP and real-world data use.
Oncology Innovation, real-world data, and precision medicine: Pierre ... Ahead of ASCO 2025, Pierre Fabre charts bold progress in NSCLC with targeted therapies, real-world data, and innovative partnerships
Oncology AACR 2025: New modalities and remaining challenges Explore the latest advancements and challenges in ADC therapy at AACR 2025: New modalities and remaining challenges
Spotlight on ASCO 2025 As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content coming to you from onsite in Chicago. We’ll have features and video content rolling out as the presentations unfold day by day.
Oncology The mesenchymal stem cell’s superpower: Hacking the TME What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) could disrupt this shield.
R&D Ben Sidders on integrating causality in AI for R&D success Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
